{
  "trial_id": "NCT03445065",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, type of diabetes (Type 1 or Type 2), duration of diabetes, insulin therapy type (multiple-daily subcutaneous injections or insulin pump), baseline HbA1c, baseline mean glucose levels, time spent in hypoglycemia (<70 mg/dL), history of hepatitis B, history of hepatitis C, history of HIV, use of immunosuppressant therapy, use of chemotherapy, use of anticoagulant/antithrombotic therapy, use of antibiotics for chronic infection, need for MRI, allergy to topical or local anesthetics, allergy to glucocorticoids, use of systemic glucocorticoids, psychiatric conditions, history of alcohol abuse, history of drug abuse, participation in another clinical investigation, legal competence, dependency on sponsor or investigator, presence of other active implanted devices.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Type of Diabetes",
          "type of diabetes (Type 1 or Type 2)"
        ],
        [
          "Hemoglobin A1c (HbA1c, %) Levels at Baseline",
          "baseline HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected",
        "Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 0 to Day 30"
      ],
      "remaining_candidate_features": [
        "duration of diabetes",
        "insulin therapy type (multiple-daily subcutaneous injections or insulin pump)",
        "baseline mean glucose levels",
        "time spent in hypoglycemia (<70 mg/dL)",
        "history of hepatitis B",
        "history of hepatitis C",
        "history of HIV",
        "use of immunosuppressant therapy",
        "use of chemotherapy",
        "use of anticoagulant/antithrombotic therapy",
        "use of antibiotics for chronic infection",
        "need for MRI",
        "allergy to topical or local anesthetics",
        "allergy to glucocorticoids",
        "use of systemic glucocorticoids",
        "psychiatric conditions",
        "history of alcohol abuse",
        "history of drug abuse",
        "participation in another clinical investigation",
        "legal competence",
        "dependency on sponsor or investigator",
        "presence of other active implanted devices"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Type of Diabetes (Type 1 or Type 2), Duration of Diabetes, Baseline HbA1c, Insulin Therapy Type (MDI or Pump), Daily Insulin Dose, Time Spent in Hypoglycemia,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Type of Diabetes",
          "Type of Diabetes (Type 1 or Type 2)"
        ],
        [
          "Hemoglobin A1c (HbA1c, %) Levels at Baseline",
          "Baseline HbA1c"
        ],
        [
          "Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 0 to Day 30",
          "Time Spent in Hypoglycemia"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Duration of Diabetes",
        "Insulin Therapy Type (MDI or Pump)",
        "Daily Insulin Dose"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Diabetes Type, Diabetes Duration, HbA1c, Insulin Therapy, BMI, Region of Enrollment.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Type of Diabetes",
          "Diabetes Type"
        ],
        [
          "Hemoglobin A1c (HbA1c, %) Levels at Baseline",
          "HbA1c"
        ]
      ],
      "remaining_reference_features": [
        "Race and Ethnicity Not Collected",
        "Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 0 to Day 30"
      ],
      "remaining_candidate_features": [
        "Diabetes Duration",
        "Insulin Therapy",
        "BMI",
        "Region of Enrollment"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, diabetes type (Type 1 or Type 2), duration of diabetes, insulin therapy type (multiple-daily subcutaneous injections or insulin pump), HbA1c level, body mass index (BMI), mean glucose level, percentage of time spent in hypoglycemia, history of hypoglycemic events, comorbidities, concomitant medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Type of Diabetes",
          "diabetes type (Type 1 or Type 2)"
        ],
        [
          "Hemoglobin A1c (HbA1c, %) Levels at Baseline",
          "HbA1c level"
        ],
        [
          "Percentage of Time Spent in Hypoglycemia (<54 mg/dL) From Day 0 to Day 30",
          "percentage of time spent in hypoglycemia"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race and Ethnicity Not Collected"
      ],
      "remaining_candidate_features": [
        "duration of diabetes",
        "insulin therapy type (multiple-daily subcutaneous injections or insulin pump)",
        "body mass index (BMI)",
        "mean glucose level",
        "history of hypoglycemic events",
        "comorbidities",
        "concomitant medications"
      ]
    }
  }
}